Lauren is Aceragen’s Vice President of Clinical Operations and brings to the team over 25 years of pharmaceutical development experience. Her career started as a clinical monitor with Covance which eventually led to oversight of clinical and medical affairs operations teams at Wyeth, Pfizer, Cephalon and Teva across multiple therapeutic areas. Her biotech experience includes
Craig is Head of Biometrics at Aceragen and oversees ongoing Clinical Data Management and Biostatistics work. He is a Certified Clinical Data Manager with over 20 years combined knowledge and experience in the Pharmaceutical and Biotechnology Industries. Craig has worked at large pharmaceutical companies (Merck, Sanofi-Aventis, Shire), CRO (MDS/INC), and small biotech companies (ViroPharma, Idera
Christina Amendola serves as Aceragen’s Director of Human Resources. Prior to joining the team, Christina served as Human Resources Manager at Idera Pharmaceuticals, where she worked strategically with senior leaders and cross functional teams to support business objectives. She held roles of increasing responsibility in HR and drove talent management, performance management, talent acquisition, inclusion
John is Aceragen’s Chief Financial Officer, having held the same role at Idera Pharmaceuticals since 2019 and transitioning to the Aceragen team as part of the 2022 merger between the two companies. He has gained more than 25 years of public-company finance and business experience from his roles in public accounting and with small to
Deepa leads the Quality function at Aceragen and oversees quality and compliance related activities for GMP and GCP operations. In her previous Quality leadership positions, she implemented Quality Systems for various early through late phase clinical development process, provided key CMO and CRO Oversight, and conducted GxP Audits for various biotech organizations. Deepa brings nearly
Nils is the Vice President of Medical and Patient Strategies, joining Aceragen from BridgeBio where he developed Medical Affairs for rare disease programs. His prior experience includes building Medical Affairs capabilities and teams, with significant experience in the area of improving patient diagnosis capabilities. He holds and PhD in Biomedical Research from the University of
Adam is a biopharma executive with extensive expertise in clinical, regulatory, non-clinical, CMC and commercial sciences. He will lead Aceragen’s Early Development activities, such as the identification and development of novel indications for our current pipeline programs. He will also direct evaluation and support of new opportunities that fit within Aceragen’s mission to address rare
Hien-Anh focuses on technical operations for novel therapeutics discovery and development. She has a track-record of building multiple teams and facilities to support drug discovery, pre-clinical studies and GMP drug manufacturing. Prior to joining Aceragen, she managed the core R&D services at Exicure, assembled the tissue culture division at SAMDI Tech Inc, and led technical
Annie serves as a Regulatory Affair Associate Director. She is responsible for supporting regulatory strategy implementation from pre-IND to post-approval. In her 10 years of biopharma experience, Annie worked on multiple key functions relating to manufacture of biologics including process characterization, validation, technology transfers, GMP investigations and critical raw material assessments. She holds a doctorate
Kara serves as Executive Administrator and Accounting Associate in the finance department. Aceragen is her first foray into the world of biotechnology. She’s been an entrepreneur, a NASA research fellow, a graphic artist and a mathematical copy editor. With degrees in aeronautics & astronautics and materials science & engineering from the Massachusetts Institute of Technology,
